TW200633710A - Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor - Google Patents
Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptorInfo
- Publication number
- TW200633710A TW200633710A TW094142668A TW94142668A TW200633710A TW 200633710 A TW200633710 A TW 200633710A TW 094142668 A TW094142668 A TW 094142668A TW 94142668 A TW94142668 A TW 94142668A TW 200633710 A TW200633710 A TW 200633710A
- Authority
- TW
- Taiwan
- Prior art keywords
- fluorinated
- alkyl
- dopamine
- cycloalkyl
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63241204P | 2004-12-02 | 2004-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200633710A true TW200633710A (en) | 2006-10-01 |
Family
ID=35976712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW094142668A TW200633710A (en) | 2004-12-02 | 2005-12-02 | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8101754B2 (zh) |
| EP (1) | EP1817037B1 (zh) |
| JP (1) | JP5049134B2 (zh) |
| KR (1) | KR20070106989A (zh) |
| CN (1) | CN101384263A (zh) |
| AU (1) | AU2005311452A1 (zh) |
| BR (1) | BRPI0518823A2 (zh) |
| CA (1) | CA2588457A1 (zh) |
| ES (1) | ES2417488T3 (zh) |
| IL (1) | IL183542A0 (zh) |
| MX (1) | MX2007006598A (zh) |
| TW (1) | TW200633710A (zh) |
| WO (1) | WO2006058753A1 (zh) |
| ZA (1) | ZA200705008B (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040204422A1 (en) | 2003-04-14 | 2004-10-14 | Abbott Gmbh & Co. Kg. | N-[(Piperazinyl)hetaryl]arylsulfonamide compounds |
| MX2007001530A (es) * | 2004-08-09 | 2007-04-23 | Abbott Gmbh & Co Kg | Compuestos de 4-piperazinil-pirimidina adecuados para tratar trastornos que responde a la modulacion del receptor dopamina d3. |
| ES2417488T3 (es) * | 2004-12-02 | 2013-08-08 | Abbott Gmbh & Co. Kg | Compuestos de triazol adecuados para tratar trastornos que responden a la modulación del receptor de dopamina D3 |
| GB0517193D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Novel use |
| WO2007099828A1 (ja) * | 2006-02-23 | 2007-09-07 | Shionogi & Co., Ltd. | 環式基で置換された含窒素複素環誘導体 |
| EP2170334B1 (en) * | 2007-06-29 | 2021-03-17 | Emory University | Nmda receptor antagonists for neuroprotection |
| PA8802101A1 (es) * | 2007-11-02 | 2009-08-26 | Abbott Gmbh & Co Kg | Compuestos de 1,2,4-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4425144A1 (de) * | 1994-07-15 | 1996-01-18 | Basf Ag | Triazolverbindungen und deren Verwendung |
| US6403593B1 (en) * | 1995-07-14 | 2002-06-11 | Abbott Laboratories | Triazole compounds and the use thereof |
| DE19728996A1 (de) * | 1997-07-07 | 1999-01-14 | Basf Ag | Triazolverbindungen und deren Verwendung |
| AR022228A1 (es) | 1999-01-12 | 2002-09-04 | Abbott Gmbh & Co Kg | Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para la preparar dicha composicion |
| GB0212399D0 (en) * | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Compounds |
| JP2004359689A (ja) * | 2003-06-05 | 2004-12-24 | Abbott Gmbh & Co Kg | ドーパミンｄ３受容体のモジュレーションに反応する障害の治療に適するトリアゾール化合物 |
| US6919342B2 (en) * | 2003-06-05 | 2005-07-19 | Abbott Gmbh & Co. Kg | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
| EP1766407A2 (en) | 2004-06-18 | 2007-03-28 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells |
| ES2417488T3 (es) * | 2004-12-02 | 2013-08-08 | Abbott Gmbh & Co. Kg | Compuestos de triazol adecuados para tratar trastornos que responden a la modulación del receptor de dopamina D3 |
-
2005
- 2005-12-01 ES ES05823049T patent/ES2417488T3/es active Active
- 2005-12-01 US US11/792,596 patent/US8101754B2/en not_active Expired - Fee Related
- 2005-12-01 BR BRPI0518823-7A patent/BRPI0518823A2/pt not_active IP Right Cessation
- 2005-12-01 JP JP2007543780A patent/JP5049134B2/ja not_active Expired - Fee Related
- 2005-12-01 AU AU2005311452A patent/AU2005311452A1/en not_active Abandoned
- 2005-12-01 KR KR1020077015182A patent/KR20070106989A/ko not_active Application Discontinuation
- 2005-12-01 CA CA002588457A patent/CA2588457A1/en not_active Abandoned
- 2005-12-01 CN CNA2005800474986A patent/CN101384263A/zh active Pending
- 2005-12-01 WO PCT/EP2005/012856 patent/WO2006058753A1/en active Application Filing
- 2005-12-01 EP EP05823049A patent/EP1817037B1/en active Active
- 2005-12-01 MX MX2007006598A patent/MX2007006598A/es not_active Application Discontinuation
- 2005-12-02 TW TW094142668A patent/TW200633710A/zh unknown
-
2007
- 2007-05-29 IL IL183542A patent/IL183542A0/en unknown
- 2007-06-01 ZA ZA200705008A patent/ZA200705008B/xx unknown
-
2011
- 2011-12-21 US US13/333,702 patent/US20120095015A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2417488T3 (es) | 2013-08-08 |
| EP1817037A1 (en) | 2007-08-15 |
| US20120095015A1 (en) | 2012-04-19 |
| US20080171751A1 (en) | 2008-07-17 |
| EP1817037B1 (en) | 2013-04-03 |
| IL183542A0 (en) | 2007-09-20 |
| KR20070106989A (ko) | 2007-11-06 |
| WO2006058753A1 (en) | 2006-06-08 |
| JP5049134B2 (ja) | 2012-10-17 |
| CN101384263A (zh) | 2009-03-11 |
| BRPI0518823A2 (pt) | 2008-12-09 |
| CA2588457A1 (en) | 2006-06-08 |
| AU2005311452A1 (en) | 2006-06-08 |
| MX2007006598A (es) | 2007-09-21 |
| US8101754B2 (en) | 2012-01-24 |
| JP2008521859A (ja) | 2008-06-26 |
| ZA200705008B (en) | 2008-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200633710A (en) | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | |
| TW200728292A (en) | Pyrazinecarboxamide derivatives and plant disease controlling agents containing the same | |
| WO2007125321A3 (en) | Purine and deazapurine derivatives as pharmaceutical compounds | |
| PT1221444E (pt) | Derivados de imidazole condensados e medicamentos para a diabetes mellitus | |
| CA2554550A1 (en) | Hydroisoindoline tachykinin receptor antagonists | |
| MXPA04009497A (es) | Piridinoilpiperidinas como antagonistas de 5-ht1f. | |
| MY146532A (en) | Thiazole derivative | |
| DE602005005167D1 (de) | 1-isopropyl-2-oxo-1,2-dihydropyridin-3-carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor | |
| CO5670367A2 (es) | Derivados de acido fenoxiacetico | |
| EA200601830A1 (ru) | Ортозамещённые арильные или гетероарильные амидные соединения | |
| TW200637539A (en) | CTGF inhibitors | |
| AU2006325931A8 (en) | Amine compound and use thereof for medical purposes | |
| IL180171A0 (en) | Novel 2-substituted d-homo-estra-1,3,5(10)-trienes as inhibitors of 17??- hydroxysteroid dehydrogenase type 1 | |
| TW200745033A (en) | Oxindole derivative as feeding control agent | |
| HK1048303A1 (en) | Aminobenzophenoses as inhibitors of il-1b and tnf -a. | |
| TW200735864A (en) | Immediate release pharmaceutical formulation | |
| TW200628437A (en) | Aminoindane dopamine D3 receptor antagonists | |
| AP9901578A0 (en) | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents. | |
| MXPA06002767A (es) | 2-carbonilamino-6-piperidinaminopiridinas substituidas y 1-carbonilamino-3-piperidinaminobenzenos y sustituidos como agonistas de 5-ht1f. | |
| MY154066A (en) | 1,2,4,-triazin-3,5-dione compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor | |
| TW200510395A (en) | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | |
| TW200616679A (en) | Modified-release preparation | |
| TW200626571A (en) | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | |
| WO2007000392A3 (en) | Chloro-substituted guanidines | |
| EA200200682A1 (ru) | Новые соединения n-бензилпиперазина, способ их получения и фармацевтические композиции, их содержащие |